<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25088" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Metoclopramide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Isola</surname>
            <given-names>Sasank</given-names>
          </name>
          <aff>Kern Medical</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hussain</surname>
            <given-names>Azhar</given-names>
          </name>
          <aff>Touro College of Pharmacy</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dua</surname>
            <given-names>Anterpreet</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Karampal</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adams</surname>
            <given-names>Ninos</given-names>
          </name>
          <aff>Kern Medical</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sasank Isola declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Azhar Hussain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anterpreet Dua declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karampal Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ninos Adams declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25088.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Metoclopramide is a dopamine receptor antagonist and has been approved by the FDA to treat nausea and vomiting in patients with gastroesophageal reflux disease or diabetic gastroparesis by increasing gastric motility. It is also used to control nausea and vomiting in chemotherapy patients. Additionally, metoclopramide can be administered prophylactically to prevent nausea and vomiting in postoperative patients when nasogastric suction is contraindicated or unavailable and has shown surprising success in treating migraines; however, the FDA has not explicitly approved it for these other conditions. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of metoclopramide, pertinent for interprofessional team members in treating patients with conditions that are of clinical value.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanisms of action of metoclopramide.</p></list-item><list-item><p>Identify the approved and off-label indications for metoclopramide.</p></list-item><list-item><p>Review the potential adverse events associated with metoclopramide.</p></list-item><list-item><p>Summarize the contraindications to therapy with metoclopramide.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25088&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25088">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25088.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The FDA has approved metoclopramide to treat nausea and vomiting in patients with gastroesophageal reflux disease (in patients&#x000a0;who fail to respond to established therapy)&#x000a0;and&#x000a0;diabetic gastroparesis by increasing gastric motility.<xref ref-type="bibr" rid="article-25088.r1">[1]</xref><xref ref-type="bibr" rid="article-25088.r2">[2]</xref>&#x000a0;Parenteral metoclopramide is also FDA approved to control nausea and vomiting in chemotherapy patients.<xref ref-type="bibr" rid="article-25088.r3">[3]</xref><xref ref-type="bibr" rid="article-25088.r4">[4]</xref></p>
        <p>Metoclopramide is used off-label prophylactically to prevent nausea and vomiting in postoperative patients when nasogastric suction is contraindicated or unavailable. It is particularly&#x000a0;useful in this role because it does not cause any concomitant increase in gastric secretions.<xref ref-type="bibr" rid="article-25088.r5">[5]</xref>&#x000a0;Metoclopramide is also used off-label to treat acute migraine in the emergency department. It is an effective adjunctive agent for acute nausea and vomiting and reduces headache intensity; hence it is a valuable agent for the short-term&#x000a0;treatment of&#x000a0;acute migraine in the ED.&#x000a0;It is important to recognize that FDA has not explicitly approved it for acute migraine. Still, it is a valuable alternative to opioids&#x000a0;due to the potential for opioid&#x000a0;use disorder.<xref ref-type="bibr" rid="article-25088.r6">[6]</xref><xref ref-type="bibr" rid="article-25088.r7">[7]</xref></p>
        <p>Metoclopramide can also be used off-label to&#x000a0;treat hyperemesis gravidarum in pregnant patients; still, it should be used cautiously because of the lack of studies on the effects of the drug in pregnant women.<xref ref-type="bibr" rid="article-25088.r8">[8]</xref><xref ref-type="bibr" rid="article-25088.r9">[9]</xref>&#x000a0;Recent studies have also shown evidence of metoclopramide&#x02019;s efficacy in treating Diamond Blackfan syndrome.<xref ref-type="bibr" rid="article-25088.r10">[10]</xref><xref ref-type="bibr" rid="article-25088.r11">[11]</xref>&#x000a0;Metoclopramide has also been efficacious in treating nausea in critically ill advanced liver disease patients.<xref ref-type="bibr" rid="article-25088.r12">[12]</xref></p>
      </sec>
      <sec id="article-25088.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Metoclopramide works by antagonizing central and peripheral dopamine-two receptors (D2) in the medullary chemoreceptor trigger zone in the area postrema, usually stimulated by levodopa or apomorphine. It achieves this by decreasing the sensitivity of visceral afferent nerves that transmit from the gastrointestinal system to the vomiting center in the area postrema in the chemoreceptor trigger zone.<xref ref-type="bibr" rid="article-25088.r13">[13]</xref>&#x000a0;In addition to antagonizing dopamine receptors, metoclopramide&#x000a0;is an antagonist at&#x000a0;5HT3 (type 3 serotonin receptors) and an agonist at&#x000a0;5HT4 receptors.<xref ref-type="bibr" rid="article-25088.r14">[14]</xref><xref ref-type="bibr" rid="article-25088.r15">[15]</xref>&#x000a0;Metoclopramide also blocks the antiperistaltic effects of apomorphine, allowing metoclopramide to slow apomorphine's inhibition of gastric emptying, thereby&#x000a0;accelerating gastric emptying by increasing the amplitude and duration of esophageal contractions.&#x000a0;Consequently, it increases the resting tone of the lower esophageal sphincter while simultaneously relaxing the duodenal bulb and pyloric sphincter, thereby&#x000a0;increasing the peristalsis of the duodenum and jejunum.<xref ref-type="bibr" rid="article-25088.r16">[16]</xref><xref ref-type="bibr" rid="article-25088.r17">[17]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>Metoclopramide is rapidly and well absorbed from the gastrointestinal tract, and peak plasma concentrations&#x000a0;are attained about 1 to 2 hours after the oral dose.&#x000a0;Metoclopramide is lipid-soluble, giving it a large half-life&#x000a0;and a large volume of distribution. Its half-life&#x000a0;can range from 4.5 hours to 8.8 hours.<xref ref-type="bibr" rid="article-25088.r18">[18]</xref></p>
        <p><bold>Distribution: </bold>The volume of distribution is high (approximately 3.5 L/kg), which suggests the extensive distribution of drugs to the tissues.<xref ref-type="bibr" rid="article-25088.r19">[19]</xref></p>
        <p><bold>Metabolism: </bold>Metoclopramide is metabolized by&#x000a0;oxidation primarily via cytochrome P450 2D6 (CYP2D6), glucuronide, and sulfate conjugation.<xref ref-type="bibr" rid="article-25088.r20">[20]</xref></p>
        <p><bold>Excretion: </bold>In a study, approximately 85% of the radioactivity of an orally administered dose is recovered in the urine, and half of it is present as a parent or conjugated metoclopramide. Around 18&#x02013;22% of the dose&#x000a0;is recovered as free metoclopramide in urine. Metoclopramide's elimination half-life in adults with normal renal function has been reported to be ~ 6 hours. In adults with severe renal impairment, there is a reduced metoclopramide clearance, increasing&#x000a0;the elimination half-life (7.7&#x000a0;to 17.8 hours).<xref ref-type="bibr" rid="article-25088.r14">[14]</xref></p>
      </sec>
      <sec id="article-25088.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Metoclopramide is generally administered orally in a tablet or solution form.&#x000a0;The dosage of the tablets and solutions is generally&#x000a0;5&#x000a0;to 10 mg. It is usually taken before meals and before sleep. However, it can be administered intramuscularly or intravenously in severely nauseous patients; the intravenous route takes effect much more quickly.<xref ref-type="bibr" rid="article-25088.r13">[13]</xref>&#x000a0;Parenteral metoclopramide is also 5 mg. Rectal administration is also an option, as is an intraperitoneal injection in patients undergoing peritoneal dialysis.<xref ref-type="bibr" rid="article-25088.r21">[21]</xref>&#x000a0;The&#x000a0;USFDA also approved metoclopramide nasal spray for symptomatic&#x000a0;relief in adults with acute and recurrent diabetic gastroparesis. The nasal formulation has a unique benefit; it can be absorbed without depending on the&#x000a0;absorption in the state of gastroparesis,&#x000a0;thus ensuring the delivery of a therapeutic dose of metoclopramide.<xref ref-type="bibr" rid="article-25088.r22">[22]</xref></p>
        <p>Metoclopramide dosing for&#x000a0;various indications is as follows:</p>
        <p><bold>Diabetic Gastroparesis:</bold> 10 mg orally/IV/IM four times daily for a maximum duration of 12 weeks; max dose is 40 mg daily.&#x000a0;Start at 5 mg four times daily for geriatric patients. For patients who are poor CYP2D6 metabolizers, give 5 mg four times daily (30 minutes before meals and at bedtime) with a max dose of 20 mg daily.<xref ref-type="bibr" rid="article-25088.r2">[2]</xref></p>
        <p><bold>GERD (chronic):</bold> 10 to 15 mg orally/IM/IV four times daily for a maximum duration of 12 weeks; maximum dose of 60 mg daily. Start at 5 mg four times daily for geriatric patients; max dose 30 mg daily. For patients who are poor CYP2D6 metabolizers, give 5 mg four times daily (30 minutes before meals and at bedtime) or 10 mg three times daily (30 minutes before meals).</p>
        <p><bold>GERD (intermittent): </bold>Up to 20 mg orally/IV/IM&#x000a0;for one dose before symptoms begin.</p>
        <p><bold>Prophylaxis of Chemotherapy-related Nausea and Vomiting:</bold>&#x000a0;1 to 2 mg/kg/dose IV every 2 to 3 hours; the first dose is given 30 minutes before starting chemotherapy, then repeated for two doses every 2 hours, then three doses every 3 hours. Pretreat with diphenhydramine to reduce extrapyramidal symptoms. Metoclopramide is not a first-line agent for this purpose.</p>
        <p>
<bold>Use in Specific Patient Populations</bold>
</p>
        <p><bold>Patients with Hepatic Impairment: </bold>Reduce the dose of metoclopramide in patients with moderate or severe hepatic impairment (Child-Pugh B or C). The recommended dose for diabetic gastroparesis is&#x000a0;5 mg&#x000a0;four times daily.</p>
        <p><bold>Patients with Renal Impairment:</bold> In patients with kidney failure, it is generally recommended that metoclopramide maintenance doses be reduced to avoid drug accumulation.<xref ref-type="bibr" rid="article-25088.r23">[23]</xref>&#x000a0;Use caution in moderate or severe renal impairment (creatinine clearance&#x0003c;60 mL/minute). In patients with end-stage renal disease requiring&#x000a0;hemodialysis, the maximum recommended dose is 5 mg twice daily. Lifestyle modification in the form of smaller and more frequent meals is first-line therapy.&#x000a0;According to the American society of nephrology guidelines, metoclopramide&#x000a0;can be used at 2.5 mg every four hours in refractory cases.<xref ref-type="bibr" rid="article-25088.r24">[24]</xref></p>
        <p><bold>Pregnancy Considerations:&#x000a0;</bold>Metoclopramide can&#x000a0;cross the placental barrier. Maternal administration of metoclopramide during delivery can lead to extrapyramidal signs and methemoglobinemia in neonates. According to ACOG(The American College of Obstetricians and Gynecologists) guidelines, metoclopramide should be used only in refractory cases of nausea and vomiting during pregnancy, 5&#x000a0;to 10 mg every 6&#x000a0;to 8 hours, orally or intramuscularly, in adequately hydrated patients. The preferred&#x000a0;pharmacological management is pyridoxine(vitamin B6) or pyridoxine in combination with doxylamine.<xref ref-type="bibr" rid="article-25088.r25">[25]</xref></p>
        <p><bold>Breastfeeding Considerations:&#x000a0;</bold>Metoclopramide is used as a galactagogue, but&#x000a0;the clinical value of metoclopramide in increasing milk supply is uncertain. A meta-analysis of eight clinical trials&#x000a0;indicated&#x000a0;that metoclopramide increased serum prolactin but did not increase milk supply. Metoclopramide use increases the risk of postpartum depression and tardive dyskinesia. Use with caution.<xref ref-type="bibr" rid="article-25088.r26">[26]</xref></p>
      </sec>
      <sec id="article-25088.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of metoclopramide use include extrapyramidal symptoms.<xref ref-type="bibr" rid="article-25088.r27">[27]</xref><xref ref-type="bibr" rid="article-25088.r28">[28]</xref>&#x000a0;These include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute dystonic reactions
<list list-type="bullet"><list-item><p>Torticollis</p></list-item><list-item><p>Trismus</p></list-item><list-item><p>Opisthotonus</p></list-item><list-item><p>Akathisia</p></list-item><list-item><p>Dystonia</p></list-item><list-item><p>Oculogyric crisis</p></list-item><list-item><p>Laryngospasm</p></list-item><list-item><p>Hyperprolactinemia</p></list-item><list-item><p>Tardive dyskinesia</p></list-item><list-item><p>Parkinson symptoms</p></list-item><list-item><p>Neuroleptic malignant syndrome&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Neuroleptic malignant syndrome is a rare adverse effect.<xref ref-type="bibr" rid="article-25088.r29">[29]</xref>&#x000a0;It is among the most serious adverse reactions because it manifests as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperthermia</p>
          </list-item>
          <list-item>
            <p>Lead pipe rigidity</p>
          </list-item>
          <list-item>
            <p>Leukocytosis</p>
          </list-item>
          <list-item>
            <p>Elevated creatine phosphokinase levels</p>
          </list-item>
          <list-item>
            <p>Altered consciousness</p>
          </list-item>
          <list-item>
            <p>Symptoms of autonomic instability (potentially)&#x000a0;</p>
          </list-item>
        </list>
        <p>
<list list-type="bullet"><list-item><p>Diaphoresis</p></list-item><list-item><p>Tachycardia</p></list-item><list-item><p>Incontinence</p></list-item><list-item><p>Pallor</p></list-item><list-item><p>Irregular blood pressure or pulse</p></list-item><list-item><p>Cardiac arrhythmias</p></list-item></list>
</p>
        <p>Thus, any patient on metoclopramide who develops neuroleptic malignant syndrome should have metoclopramide immediately discontinued and undergo treatment with dantrolene. These adverse effects stem from metoclopramide&#x02019;s anti-dopaminergic mechanism of action. It is important to note that these adverse effects are dose-independent and generally&#x000a0;reversible following discontinuation of the drug.<xref ref-type="bibr" rid="article-25088.r30">[30]</xref>&#x000a0;Furthermore, it is important to keep in mind that oculogyric crises caused by metoclopramide can resemble the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Cranial nerve palsies</p>
          </list-item>
          <list-item>
            <p>Paroxysmal tonic upward gaze</p>
          </list-item>
          <list-item>
            <p>Encephalopathy<xref ref-type="bibr" rid="article-25088.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>Metoclopramide-induced hyperprolactinemia can cause&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gynecomastia</p>
          </list-item>
          <list-item>
            <p>Galactorrhea</p>
          </list-item>
          <list-item>
            <p>Amenorrhea</p>
          </list-item>
          <list-item>
            <p>Impotence</p>
          </list-item>
          <list-item>
            <p>Hypogonadism</p>
          </list-item>
        </list>
        <p>In patients with glucose-6-phosphate dehydrogenase deficiency or nicotinamide adenine dinucleotide cytochrome b5 reductase deficiency, metoclopramide can cause methemoglobinemia and sulfhemoglobinemia.<xref ref-type="bibr" rid="article-25088.r32">[32]</xref><xref ref-type="bibr" rid="article-25088.r33">[33]</xref>&#x000a0;Additionally, metoclopramide can increase serum aldosterone levels, potentially causing fluid retention and volume overload. Therefore, it must be used with caution in patients with heart failure or cirrhosis of the liver.<xref ref-type="bibr" rid="article-25088.r34">[34]</xref>&#x000a0;Metoclopramide has also been shown to cause a non-thrombocytopenic purpuric rash that subsides upon discontinuation of the drug.<xref ref-type="bibr" rid="article-25088.r35">[35]</xref></p>
        <p>Less acute adverse effects of metoclopramide, generally reversible and observed in children, include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sedation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Diarrhea<xref ref-type="bibr" rid="article-25088.r36">[36]</xref></p>
          </list-item>
        </list>
        <p>Rarer psychiatric side effects that have&#x000a0;developed following brief&#x000a0;exposure to metoclopramide include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Panic disorder</p>
          </list-item>
          <list-item>
            <p>Major depressive disorder</p>
          </list-item>
          <list-item>
            <p>Agoraphobia<xref ref-type="bibr" rid="article-25088.r37">[37]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Reduced efficacy of dopamine agonists(like bromocriptine and cabergoline)<xref ref-type="bibr" rid="article-25088.r38">[38]</xref>&#x000a0;Furthermore, metoclopramide can increase serum aspirin levels by increasing the absorption of aspirin, potentially causing salicylate toxicity.<xref ref-type="bibr" rid="article-25088.r39">[39]</xref>&#x000a0;In addition to increasing the absorption of aspirin, metoclopramide can also increase serum levels of bupropion and its metabolite&#x000a0;hydroxybupropion&#x000a0;because it aids gastric emptying and thus bupropion absorption in the small intestine.<xref ref-type="bibr" rid="article-25088.r40">[40]</xref>&#x000a0;This can increase the serum levels of other drugs, given that bupropion and hydroxybupropion, in turn, inhibit the effects of the CYP2D6 metabolic enzyme.<xref ref-type="bibr" rid="article-25088.r41">[41]</xref>&#x000a0;</p>
        <p>Concurrent administration of&#x000a0;metoclopramide and antipsychotic&#x000a0;drugs should be avoided due to the potential for additive effects and neuroleptic malignant syndrome(NMS).<xref ref-type="bibr" rid="article-25088.r42">[42]</xref>&#x000a0;Metoclopramide&#x000a0;should not be administered with&#x000a0;CYP2D6 inhibitors like fluoxetine as there is an increased risk of extrapyramidal symptoms.<xref ref-type="bibr" rid="article-25088.r43">[43]</xref></p>
      </sec>
      <sec id="article-25088.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Metoclopramide is contraindicated in patients with the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Known hypersensitivity to metoclopramide or excipients<xref ref-type="bibr" rid="article-25088.r44">[44]</xref></p>
          </list-item>
          <list-item>
            <p>Gastrointestinal bleeding&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Obstruction&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Perforation<xref ref-type="bibr" rid="article-25088.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>Other contraindications include&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pheochromocytoma</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Depression</p>
          </list-item>
          <list-item>
            <p>Parkinson disease</p>
          </list-item>
        </list>
        <p>Metoclopramide is contraindicated in patients with depression because&#x000a0;it can cause major depressive disorder.<xref ref-type="bibr" rid="article-25088.r37">[37]</xref>&#x000a0;It is contraindicated in patients with seizures because it lowers the seizure threshold and can result in longer and more frequent seizures.<xref ref-type="bibr" rid="article-25088.r45">[45]</xref>&#x000a0;It is contraindicated in patients with depression and Parkinson disease because of the&#x000a0;aforementioned adverse effects of major depressive disorder and parkinsonian symptoms. It is contraindicated in pheochromocytoma because it releases catecholamines and can exacerbate pheochromocytoma, causing a hypertensive crisis, which can be treated with phentolamine.<xref ref-type="bibr" rid="article-25088.r46">[46]</xref><xref ref-type="bibr" rid="article-25088.r45">[45]</xref></p>
        <p><bold>US Boxed Warning:&#x000a0;</bold>Metoclopramide can cause tardive dyskinesia, a serious movement disorder. Tardive dyskinesia risk increases with the total treatment duration and total cumulative exposure. Therefore, avoid&#x000a0;treatment with metoclopramide tablets for longer than 12 weeks. Discontinue metoclopramide in patients who develop clinical signs or symptoms of tardive dyskinesia. In some patients, symptoms may&#x000a0;decrease or resolve after metoclopramide is discontinued.<xref ref-type="bibr" rid="article-25088.r47">[47]</xref><xref ref-type="bibr" rid="article-25088.r48">[48]</xref></p>
      </sec>
      <sec id="article-25088.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>It is also important to note that the efficacy of metoclopramide can be diminished if the patient takes anticholinergics or narcotic analgesic medications because these drugs decrease the gastric emptying rate.<xref ref-type="bibr" rid="article-25088.r49">[49]</xref>&#x000a0;Metoclopramide decreases the absorption rate of drugs&#x000a0;generally absorbed from the stomach,&#x000a0;like digoxin,&#x000a0;while increasing the absorption of drugs absorbed from the small intestine, like cyclosporine.<xref ref-type="bibr" rid="article-25088.r50">[50]</xref><xref ref-type="bibr" rid="article-25088.r51">[51]</xref></p>
        <p>Metoclopramide is included in the KIDS list (Key Potentially Inappropriate Drugs in Pediatrics), a reference&#x000a0;tool to identify medications associated with a high risk for adverse drug reactions. Monitor when metoclopramide is used in pediatric patients.<xref ref-type="bibr" rid="article-25088.r52">[52]</xref>&#x000a0;Metocloclopramide is also recognized as a potentially inappropriate medication for older adults per the&#x000a0;American Geriatrics Society 2019 updated Beers criteria. Monitor elderly patients for extrapyramidal symptoms and tardive dyskinesia.<xref ref-type="bibr" rid="article-25088.r53">[53]</xref></p>
      </sec>
      <sec id="article-25088.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The following are the primary symptoms of metoclopramide overdose:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sedation<xref ref-type="bibr" rid="article-25088.r54">[54]</xref></p>
          </list-item>
          <list-item>
            <p>Diarrhea<xref ref-type="bibr" rid="article-25088.r55">[55]</xref></p>
          </list-item>
          <list-item>
            <p>Extrapyramidal adverse effects (particularly tardive dyskinesia)<xref ref-type="bibr" rid="article-25088.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>Tardive dyskinesia is an adverse effect, often seen in antipsychotic medications, that generally&#x000a0;manifests as grimacing, lip-smacking, tongue flicking, and general choreoathetoid movements of the body.<xref ref-type="bibr" rid="article-25088.r56">[56]</xref>&#x000a0;Because it can sometimes be irreversible, it is the most threatening potential complication of metoclopramide overdose, and metoclopramide treatment should be discontinued in any patient who develops tardive dyskinesia. Extrapyramidal adverse effects have been&#x000a0;observed in metoclopramide overdose, particularly in infants and the elderly, who are at the most significant risk.<xref ref-type="bibr" rid="article-25088.r57">[57]</xref>&#x000a0;Retrospective analysis has shown that pediatric emergency room visits leading to extrapyramidal symptoms&#x000a0;can be caused by metoclopramide syrup overdose.<xref ref-type="bibr" rid="article-25088.r58">[58]</xref></p>
        <p>Though there is no specific treatment for metoclopramide overdose, its extrapyramidal effects are among the most common adverse effects. They can be alleviated with anticholinergics like benztropine and antihistamines like diphenhydramine.<xref ref-type="bibr" rid="article-25088.r59">[59]</xref>&#x000a0;Supportive therapy is recommended, while dialysis is generally&#x000a0;ineffective in treating metoclopramide overdose.<xref ref-type="bibr" rid="article-25088.r23">[23]</xref></p>
      </sec>
      <sec id="article-25088.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Metoclopramide is widely used in most hospitals and is an effective drug for gastroparesis and postoperative nausea and vomiting. However, the drug does have several side effects that all healthcare practitioners must be familiar with, so an interprofessional team approach is necessary. The nurse and pharmacist are in a prime position to monitor the drug and, hopefully, reduce its adverse effects by closely monitoring the patient and recommending discontinuation when symptoms arise. Of all the side effects, the most concerning are the extrapyramidal reactions that&#x000a0;are more likely to occur&#x000a0;in diabetics, children, seniors, and those already taking antipsychotic&#x000a0;medications. The risk of developing tardive dyskinesia from metoclopramide varies from 1 to 15%, and the condition is quite debilitating. Hence, before using this drug, the nurse, pharmacist, and prescriber should obtain informed consent from the patient. All patients should be told about the potential for developing dyskinesias before treatment. If the patient has an adverse risk profile, the pharmacist should offer another agent option to the prescriber for consideration.</p>
        <p>All interprofessional team members are also responsible for communicating concerns with other team members. They must also maintain accurate and updated records of their observations and interventions with the patient so that all team members have the most recent data on the case. Closely monitoring the patient is critical, and the interprofessional team, including clinicians, nursing, and pharmacy, will drive optimal outcomes.<xref ref-type="bibr" rid="article-25088.r60">[60]</xref>&#x000a0;[Level 5]</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Metoclopramide has proven valuable in managing&#x000a0;diabetic gastroparesis, postoperative nausea, and vomiting. However, the potential risk for dyskinesias has led to a re-evaluation of this agent. Experts&#x000a0;indicate that metoclopramide should be started with the lowest possible&#x000a0;dose and the shortest duration of time. The drug is effective in the short term, but its CNS&#x000a0;adverse drug reactions&#x000a0;are worrisome.<xref ref-type="bibr" rid="article-25088.r61">[61]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-25088.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25088&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25088">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25088/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25088">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25088.s11">
        <title>References</title>
        <ref id="article-25088.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rettura</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bronzini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Campigotto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lambiase</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pancetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Bortoli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zerbib</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Savarino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bellini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Refractory Gastroesophageal Reflux Disease: A Management Update.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>765061</fpage>
            <pub-id pub-id-type="pmid">34790683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shakhatreh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jehangir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Parkman</surname>
                <given-names>HP</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide for the treatment of diabetic gastroparesis.</article-title>
            <source>Expert Rev Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>711</fpage>
            <page-range>711-721</page-range>
            <pub-id pub-id-type="pmid">31314613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adel</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies.</article-title>
            <source>Am J Manag Care</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>14 Suppl</issue>
            <fpage>S259</fpage>
            <page-range>S259-S265</page-range>
            <pub-id pub-id-type="pmid">28978206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flank</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Holdsworth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Portwine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stefin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dupuis</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>63</volume>
            <issue>7</issue>
            <fpage>1144</fpage>
            <page-range>1144-51</page-range>
            <pub-id pub-id-type="pmid">26960036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Oliveira</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Castro-Alves</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yaghmour</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Systemic metoclopramide to prevent postoperative nausea and vomiting: a meta-analysis without Fujii's studies.</article-title>
            <source>Br J Anaesth</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>109</volume>
            <issue>5</issue>
            <fpage>688</fpage>
            <page-range>688-97</page-range>
            <pub-id pub-id-type="pmid">23015617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Najjar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Estupinan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide for Acute Migraine Treatment in the Emergency Department: An Effective Alternative to Opioids.</article-title>
            <source>Cureus</source>
            <year>2017</year>
            <month>Apr</month>
            <day>20</day>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>e1181</fpage>
            <pub-id pub-id-type="pmid">28533997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eigenbrodt</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Mitsikostas</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pozo-Rosich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Martelletti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ducros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lant&#x000e9;ri-Minet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Braschinsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Del Rio</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>&#x000d6;zge</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mammadbayli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arons</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Skorobogatykh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Romanenko</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Terwindt</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Paemeleire</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lampl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schytz</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of migraine in ten steps.</article-title>
            <source>Nat Rev Neurol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>501</fpage>
            <page-range>501-514</page-range>
            <pub-id pub-id-type="pmid">34145431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Khine</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Vallikkannu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Omar</surname>
                <given-names>SZ</given-names>
              </name>
            </person-group>
            <article-title>Promethazine compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial.</article-title>
            <source>Obstet Gynecol</source>
            <year>2010</year>
            <month>May</month>
            <volume>115</volume>
            <issue>5</issue>
            <fpage>975</fpage>
            <page-range>975-981</page-range>
            <pub-id pub-id-type="pmid">20410771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abas</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Azmi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Omar</surname>
                <given-names>SZ</given-names>
              </name>
            </person-group>
            <article-title>Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial.</article-title>
            <source>Obstet Gynecol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>123</volume>
            <issue>6</issue>
            <fpage>1272</fpage>
            <page-range>1272-1279</page-range>
            <pub-id pub-id-type="pmid">24807340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akiyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yanagisawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yuza</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yokoi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ariga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujisawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hoshi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Eto</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of Diamond-Blackfan anemia with metoclopramide.</article-title>
            <source>Am J Hematol</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-8</page-range>
            <pub-id pub-id-type="pmid">15795909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bierings</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>How I manage children with Diamond-Blackfan anaemia.</article-title>
            <source>Br J Haematol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>184</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-133</page-range>
            <pub-id pub-id-type="pmid">30515771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vijayaraghavan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maiwall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Choudhary</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jamwal</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Sarin</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Reversal of Feed Intolerance by Prokinetics Improves Survival in Critically Ill Cirrhosis Patients.</article-title>
            <source>Dig Dis Sci</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>67</volume>
            <issue>8</issue>
            <fpage>4223</fpage>
            <page-range>4223-4233</page-range>
            <pub-id pub-id-type="pmid">34392492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide in the treatment of diabetic gastroparesis.</article-title>
            <source>Expert Rev Endocrinol Metab</source>
            <year>2010</year>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>653</fpage>
            <page-range>653-662</page-range>
            <pub-id pub-id-type="pmid">21278804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mendley</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gerhart</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Melloni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hornik</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Atz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delmore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tremoulet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Erinjeri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cohen-Wolkowiez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>D</given-names>
              </name>
              <collab>Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee</collab>
            </person-group>
            <article-title>Population Pharmacokinetics of Metoclopramide in Infants, Children, and Adolescents.</article-title>
            <source>Clin Transl Sci</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>1189</fpage>
            <page-range>1189-1198</page-range>
            <pub-id pub-id-type="pmid">32324313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanger</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>PLR</given-names>
              </name>
            </person-group>
            <article-title>A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.</article-title>
            <source>Front Pharmacol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>913</fpage>
            <pub-id pub-id-type="pmid">30233361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramsbottom</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Studies of the effect of metoclopramide and apomorphine on gastric emptying and secretion in man.</article-title>
            <source>Gut</source>
            <year>1970</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>989</fpage>
            <page-range>989-93</page-range>
            <pub-id pub-id-type="pmid">5511820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hirosawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morinaga</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide-induced Serotonin Syndrome.</article-title>
            <source>Intern Med</source>
            <year>2017</year>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>737</fpage>
            <page-range>737-739</page-range>
            <pub-id pub-id-type="pmid">28321081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGovern</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Grevel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bryson</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of high-dose metoclopramide in cancer patients.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1986</year>
            <season>Nov-Dec</season>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>415</fpage>
            <page-range>415-24</page-range>
            <pub-id pub-id-type="pmid">3542335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blaickner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prosenz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bamminger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pichler</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tournier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hacker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeitlinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karanikas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [<sup>11</sup>C]Metoclopramide.</article-title>
            <source>Mol Imaging Biol</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>180</fpage>
            <page-range>180-185</page-range>
            <pub-id pub-id-type="pmid">33481175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chua</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Harger</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide-Induced Acute Dystonic Reactions May Be Associated With the CYP2D6 Poor Metabolizer Status and Pregnancy-Related Hormonal Changes.</article-title>
            <source>Front Pharmacol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>931</fpage>
            <pub-id pub-id-type="pmid">31507424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trapnell</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Mavko</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Birskovich</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Falko</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide suppositories in the treatment of diabetic gastroparesis.</article-title>
            <source>Arch Intern Med</source>
            <year>1986</year>
            <month>Nov</month>
            <volume>146</volume>
            <issue>11</issue>
            <fpage>2278</fpage>
            <page-range>2278-9</page-range>
            <pub-id pub-id-type="pmid">3778059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gajendran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarosiek</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>McCallum</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults.</article-title>
            <source>Expert Rev Endocrinol Metab</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>25</fpage>
            <page-range>25-35</page-range>
            <pub-id pub-id-type="pmid">33739209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lehmann</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Heironimus</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>O'Neil</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Pierson</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Crowe</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Melikian</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1985</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>284</fpage>
            <page-range>284-9</page-range>
            <pub-id pub-id-type="pmid">3971652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davison</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Tupala</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wasylynuk</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sinnarajah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Triscott</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Recommendations for the Care of Patients Receiving Conservative Kidney Management: Focus on Management of CKD and Symptoms.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>05</day>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>626</fpage>
            <page-range>626-634</page-range>
            <pub-id pub-id-type="pmid">30819670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <collab>Committee on Practice Bulletins-Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>e15</fpage>
            <page-range>e15-e30</page-range>
            <pub-id pub-id-type="pmid">29266076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r26">
          <label>26</label>
          <element-citation publication-type="book">
            <chapter-title>Metoclopramide</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moos</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide and extrapyramidal symptoms: a case report.</article-title>
            <source>J Perianesth Nurs</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>292</fpage>
            <page-range>292-9</page-range>
            <pub-id pub-id-type="pmid">18926476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donnet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harle</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Dumont</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Alif Cherif</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic malignant syndrome induced by metoclopramide.</article-title>
            <source>Biomed Pharmacother</source>
            <year>1991</year>
            <volume>45</volume>
            <issue>10</issue>
            <fpage>461</fpage>
            <page-range>461-2</page-range>
            <pub-id pub-id-type="pmid">1820178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nihalani</surname>
                <given-names>ND</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic Malignant Syndrome: A Primary Care Perspective.</article-title>
            <source>Prim Care Companion J Clin Psychiatry</source>
            <year>2004</year>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>191</fpage>
            <page-range>191-194</page-range>
            <pub-id pub-id-type="pmid">15514687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ponte</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Nappi</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Review of a new gastrointestinal drug--metoclopramide.</article-title>
            <source>Am J Hosp Pharm</source>
            <year>1981</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>829</fpage>
            <page-range>829-33</page-range>
            <pub-id pub-id-type="pmid">7018232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koban</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ekinci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cagatay</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Yazar</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Oculogyric crisis in a patient taking metoclopramide.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2014</year>
            <volume>8</volume>
            <fpage>567</fpage>
            <page-range>567-9</page-range>
            <pub-id pub-id-type="pmid">24672222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mary</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bhupalam</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide-induced methemoglobinemia in an adult.</article-title>
            <source>J Ky Med Assoc</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>98</volume>
            <issue>6</issue>
            <fpage>245</fpage>
            <page-range>245-7</page-range>
            <pub-id pub-id-type="pmid">10870338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanishima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanimoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tomoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mawatari</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsukawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoneyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohkuwa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takazakura</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Hereditary methemoglobinemia due to cytochrome b5 reductase deficiency in blood cells without associated neurologic and mental disorders.</article-title>
            <source>Blood</source>
            <year>1985</year>
            <month>Dec</month>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>1288</fpage>
            <page-range>1288-91</page-range>
            <pub-id pub-id-type="pmid">4063522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagahama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fujimaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawabe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Saruta</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Effect of metoclopramide on the secretion of aldosterone and other adrenocortical steroids.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>1983</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>287</fpage>
            <page-range>287-93</page-range>
            <pub-id pub-id-type="pmid">6861367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Upputuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide-induced delayed non-thrombocytopenic purpuric rash.</article-title>
            <source>Clin Drug Investig</source>
            <year>2006</year>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>745</fpage>
            <page-range>745-7</page-range>
            <pub-id pub-id-type="pmid">17274681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lau Moon Lin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Flank</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dupuis</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis.</article-title>
            <source>Drug Saf</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>7</issue>
            <fpage>675</fpage>
            <page-range>675-87</page-range>
            <pub-id pub-id-type="pmid">27003816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anfinson</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Akathisia, panic, agoraphobia, and major depression following brief exposure to metoclopramide.</article-title>
            <source>Psychopharmacol Bull</source>
            <year>2002</year>
            <season>Winter</season>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>82</fpage>
            <page-range>82-93</page-range>
            <pub-id pub-id-type="pmid">12397849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torre</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Falorni</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological causes of hyperprolactinemia.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>929</fpage>
            <page-range>929-51</page-range>
            <pub-id pub-id-type="pmid">18473017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volans</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>The effect of metoclopramide on the absorption of effervescent aspirin in migraine.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1975</year>
            <month>Feb</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-63</page-range>
            <pub-id pub-id-type="pmid">791318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of bupropion: a review.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1983</year>
            <month>May</month>
            <volume>44</volume>
            <issue>5 Pt 2</issue>
            <fpage>82</fpage>
            <page-range>82-4</page-range>
            <pub-id pub-id-type="pmid">6406470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joy</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Frye</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Stubbert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kharasch</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>714</fpage>
            <page-range>714-20</page-range>
            <pub-id pub-id-type="pmid">20103693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazhar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akram</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haider</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission.</article-title>
            <source>Case Rep Med</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>7128909</fpage>
            <pub-id pub-id-type="pmid">27433163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Igata</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hori</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Atake</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Katsuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2016</year>
            <volume>12</volume>
            <fpage>2279</fpage>
            <page-range>2279-81</page-range>
            <pub-id pub-id-type="pmid">27621638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pietrzko</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zakrzewski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matuszewski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kruszewski</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Angioneurotic edema: a rare case of hypersensitivity to metoclopramide.</article-title>
            <source>Postepy Dermatol Alergol</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-8</page-range>
            <pub-id pub-id-type="pmid">24278059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinstein</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Fife</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Voss</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Treem</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Chronic Metoclopramide Use and Associated Diagnoses in the US Pediatric Population.</article-title>
            <source>Paediatr Drugs</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>331</fpage>
            <page-range>331-7</page-range>
            <pub-id pub-id-type="pmid">26014368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guillemot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Compagnon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cartier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thouennon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bastard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lihrmann</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pichon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thuillez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Plouin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Bertherat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anouar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuhn</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Yon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lefebvre</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>281</fpage>
            <page-range>281-90</page-range>
            <pub-id pub-id-type="pmid">18948374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ham</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Tivis</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Caylor</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Economen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Dang</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Culbertson</surname>
                <given-names>VL</given-names>
              </name>
            </person-group>
            <article-title>MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia.</article-title>
            <source>EBioMedicine</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>26</volume>
            <fpage>132</fpage>
            <page-range>132-137</page-range>
            <pub-id pub-id-type="pmid">29191560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avalos</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sarosiek</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Loganathan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McCallum</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Diabetic gastroparesis: current challenges and future prospects.</article-title>
            <source>Clin Exp Gastroenterol</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>347</fpage>
            <page-range>347-363</page-range>
            <pub-id pub-id-type="pmid">30310300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nimmo</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Drugs, diseases and altered gastric emptying.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1976</year>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>189</fpage>
            <page-range>189-203</page-range>
            <pub-id pub-id-type="pmid">797497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Bustrack</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Urbach</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Hull</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Marwaha</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effect of metoclopramide on digoxin absorption from tablets and capsules.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1984</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>724</fpage>
            <page-range>724-30</page-range>
            <pub-id pub-id-type="pmid">6499354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wadhwa</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>O'Flaherty</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pesce</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Myre</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>First</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>The effect of oral metoclopramide on the absorption of cyclosporine.</article-title>
            <source>Transplant Proc</source>
            <year>1987</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1 Pt 2</issue>
            <fpage>1730</fpage>
            <page-range>1730-3</page-range>
            <pub-id pub-id-type="pmid">3547879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyers</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Thackray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lubsch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hellinga</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title><italic>K</italic>ey Potentially <italic>I</italic>nappropriate <italic>D</italic>rugs in Pediatrics: The KIDs List.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2020</year>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-191</page-range>
            <pub-id pub-id-type="pmid">32265601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gralla</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide. A review of antiemetic trials.</article-title>
            <source>Drugs</source>
            <year>1983</year>
            <month>Feb</month>
            <volume>25 Suppl 1</volume>
            <fpage>63</fpage>
            <page-range>63-73</page-range>
            <pub-id pub-id-type="pmid">6682376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sewell</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Jeste</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases.</article-title>
            <source>Arch Fam Med</source>
            <year>1992</year>
            <month>Nov</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>271</fpage>
            <page-range>271-8</page-range>
            <pub-id pub-id-type="pmid">1341603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Tardive dyskinesia.</article-title>
            <source>West J Med</source>
            <year>1990</year>
            <month>Nov</month>
            <volume>153</volume>
            <issue>5</issue>
            <fpage>535</fpage>
            <page-range>535-41</page-range>
            <pub-id pub-id-type="pmid">1979705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bateman</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Rawlins</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Extrapyramidal reactions with metoclopramide.</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1985</year>
            <month>Oct</month>
            <day>05</day>
            <volume>291</volume>
            <issue>6500</issue>
            <fpage>930</fpage>
            <page-range>930-2</page-range>
            <pub-id pub-id-type="pmid">3929968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Extrapyramidal Symptoms at the Pediatric Emergency Department.</article-title>
            <source>Pediatr Emerg Care</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>468</fpage>
            <page-range>468-472</page-range>
            <pub-id pub-id-type="pmid">31790070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Doja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Belanger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patten</surname>
                <given-names>S</given-names>
              </name>
              <collab>Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group</collab>
            </person-group>
            <article-title>Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth.</article-title>
            <source>Paediatr Child Health</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>590</fpage>
            <page-range>590-8</page-range>
            <pub-id pub-id-type="pmid">23115503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fog</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Kvalvaag</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Engedal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Straand</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Drug-related problems and changes in drug utilization after medication reviews in nursing homes in Oslo, Norway.</article-title>
            <source>Scand J Prim Health Care</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>329</fpage>
            <page-range>329-335</page-range>
            <pub-id pub-id-type="pmid">29096573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25088.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sridharan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sivaramakrishnan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Interventions for treating nausea and vomiting in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>1143</fpage>
            <page-range>1143-1150</page-range>
            <pub-id pub-id-type="pmid">30261764</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
